In line with our findings, previous studies have reported that inhibitors of CDK6 mediated mTOR activation [89] while combined therapy of an mTOR inhibitor and a CDK6 inhibitor synergized to achieve enhanced inhibition of tumor growth in glioblastoma [18], head and neck [90] and pancreatic [89] cancers. This evidence concerns the gene CDK6 and neoplasm.